Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2015

Open Access 01-07-2015 | Review

A model for the role of gut bacteria in the development of autoimmunity for type 1 diabetes

Authors: Austin G. Davis-Richardson, Eric W. Triplett

Published in: Diabetologia | Issue 7/2015

Login to get access

Abstract

Several lines of evidence suggest a role for the gut microbiome in type 1 diabetes. Treating diabetes-prone rodents with probiotics or antibiotics prevents the development of the disorder. Diabetes-prone rodents also have a distinctly different gut microbiome compared with healthy rodents. Recent studies in children with a high genetic risk for type 1 diabetes demonstrate significant differences in the gut microbiome between children who develop autoimmunity for the disease and those who remain healthy. However, the differences in microbiome composition between autoimmune and healthy children are not consistent across all studies because of the strong environmental influences on microbiome composition, particularly diet and geography. Controlling confounding factors of microbiome composition uncovers bacterial associations with disease. For example, in a human cohort from a single Finnish city where geography is confined, a strong association between one dominant bacterial species, Bacteroides dorei, and type 1 diabetes was discovered (Davis-Richardson et al. Front Microbiol 2014;5:678). Beyond this, recent DNA methylation analyses suggest that a thorough epigenetic analysis of the gut microbiome may be warranted. These studies suggest a testable model whereby a diet high in fat and gluten and low in resistant starch may be the primary driver of gut dysbiosis. This dysbiosis may cause a lack of butyrate production by gut bacteria, which, in turn, leads to the development of a permeable gut followed by autoimmunity. The bacterial community responsible for these changes in butyrate production may vary around the world, but bacteria of the genus Bacteroides are thought to play a key role.
Literature
1.
2.
Bosi E, Molteni L, Radaelli M et al (2006) Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49:2824–2827PubMedCrossRef
3.
Vaarala O, Atkinson M, Neu J (2008) The “perfect storm” for type 1 diabetes – the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57:2555–2562PubMedCentralPubMedCrossRef
4.
Brugman S, Klatter FA, Visser JT et al (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49:2105–2108PubMedCrossRef
5.
Schwartz RF, Neu J, Schatz D, Atkinson MA, Wasserfall C (2007) Comment on: Brugman S et al. (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49:2105–2108, Diabetologia 50: 220–221
6.
Hansen CHF, Krych L, Nielsen DS et al (2012) Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia 55:2285–2294PubMedCrossRef
7.
Roesch LF, Lorca GL, Casella G et al (2009) Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J 3:536–548PubMedCentralPubMedCrossRef
8.
9.
Lau K, Benitez P, Ardissone A et al (2011) Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias. J Immunol 186:3538–3546PubMedCrossRef
10.
Alam C, Bittoun E, Bhagwat D et al (2011) Effects of a germ-free environment on gut immune regulation and diabetes progression in non-obese diabetic (NOD) mice. Diabetologia 54:1398–1406PubMedCrossRef
11.
12.
Kriegel MA, Sefik E, Hill JA, Wu H-J, Benoist C, Mathis D (2011) Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci U S A 108:11548–11553PubMedCentralPubMedCrossRef
13.
Patrick C, Wang G-S, Lefebvre DE et al (2013) Promotion of autoimmune diabetes by cereal diet in the presence or absence of microbes associated with gut immune activation, regulatory imbalance, and altered cathelicidin antimicrobial peptide. Diabetes 62:2036–2047PubMedCentralPubMedCrossRef
14.
Sofi MH, Gudi R, Karumuthil-Melehil S, Perez N, Johnson BM, Vasu C (2014) pH of drinking water influences the composition of gut microbiome and type 1 diabetes incidence. Diabetes 63:632–644PubMedCentralPubMedCrossRef
15.
Davis-Richardson AG, Ardissone AN, Dias R et al (2014) Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. Front Microbiol 5:678PubMedCentralPubMedCrossRef
16.
Brown CT, Davis-Richardson AG, Giongo A et al (2011) Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE 6, e25792PubMedCentralPubMedCrossRef
17.
18.
Endesfelder D, zu Castell W, Ardissone A et al (2014) Compromised gut microbiota networks in children with anti-islet cell autoimmunity. Diabetes 63:2006–2014PubMedCrossRef
19.
de Goffau MC, Fuentes S, van den Bogert B (2014) Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia 57:1569–1577PubMedCrossRef
20.
21.
Goodrich JK, Waters JL, Poole AC et al (2014) Host genetics and the gut microbiome can both influence metabolic phenotypes. Cell 159:789–799PubMedCrossRef
22.
Kondrashova A, Seiskari T, Ilonen J, Knip M, Hyöty H (2012) The ‘Hygiene hypothesis’ and the sharp gradient in the incidence of autoimmune and allergic diseases between Russian Karelia and Finland. APMIS 121:478–493PubMedCrossRef
23.
Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:A355–A365PubMedCrossRef
24.
Kemppainen KM, Ardissone AN, Davis-Richardson AG et al (2015) Early childhood gut microbiomes show strong geographic differences among subjects at high risk for type 1 diabetes. Diabetes Care 38:329–332PubMedCrossRef
25.
Calixto 0-J, Anaya J-M (2014) Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev 13:641–654PubMedCrossRef
26.
Belstrom D, Holmstrup P, Nielsen CH et al (2014) Bacterial profiles of saliva in relation to diet, lifestyle factors, and socioeconomic status. J Oral Microbiol 6:23609CrossRef
27.
28.
29.
30.
Scott K, Gratz S, Sheridan P, Flint H, Duncan S (2013) The influence of diet on the gut microbiota. Pharmacol Res 69:52–60PubMedCrossRef
31.
Zimmer J, Lange B, Frick J-S et al (2011) A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 66:53–60PubMedCrossRef
32.
Sanchez E, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2010) Intestinal Bacteroides species associated with coeliac disease. J Clin Pathol 63:1105–1111PubMedCrossRef
33.
Sanchez E, de Palma G, Capilla A et al (2011) Influence of environmental and genetic factors linked to celiac disease risk on infant gut colonization by Bacteroides species. Appl Environ Microbiol 77:5316–5323PubMedCentralPubMedCrossRef
34.
McOrist AL, Miller RB, Bird AR et al (2011) Fecal butyrate levels vary widely among individuals but are usually increased by a diet high in resistant starch. J Nutr 141:883–889PubMedCrossRef
35.
Kuitunen M, Saukkonen T, Ilonen J, Akerblom HK, Savilahti E (2002) Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*02 allele. Autoimmunity 35:365–368PubMedCrossRef
36.
Sapone A, de Magistris L, Pietzak M et al (2006) Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55:1443–1449PubMedCrossRef
37.
Secondulfo M, Iafusco D, Carratu R, deMagistris L, Sapone A, Generoso M (2004) Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients. Dig Liver Dis 36:35–45PubMedCrossRef
38.
Lee AS, Gibson DL, Zhang Y, Sham HP, Vallance BA, Dutz JP (2010) Gut barrier disruption by an enteric bacterial pathogen accelerates insulitis in NOD mice. Diabetologia 53:741–748PubMedCrossRef
39.
de Kort S, Keszthelyi D, Masclee AAM (2011) Leaky gut and diabetes mellitus: what is the link? Obes Rev 12:449–458PubMedCrossRef
40.
41.
Brahe LK, Astrup A, Larsen LH (2013) Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes Rev 14:950–959PubMedCrossRef
42.
Lewis K, Lutgendorff F, Phan V, Soderholm JD, Sherman PM, McKay DM (2010) Stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 16:1138–1148PubMedCrossRef
43.
Thibault R, Blachier F, Darcy-Vrillon B, de Coppet P, Bourreille A, Segain J-P (2010) Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis 16:684–695PubMedCrossRef
44.
Burger-van Paassen N, Vincent A, Pulman PJ et al (2009) The regulation of intestinal mucin MUC2 expression by short chain fatty acids: implications for epithelial protection. Biochem J 420:211–219PubMedCrossRef
45.
Peng L, Li Z-R, Green RS, Holzman IR, Lin J (2009) Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139:1619–1625PubMedCentralPubMedCrossRef
46.
Plöger S, Stumpff F, Penner GB et al (2012) Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann NY Acad Sci 1258:52–59PubMedCrossRef
47.
de Goffau MC, Luopajarvi K, Knip M et al (2013) Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes 62:1238–1244PubMedCentralPubMedCrossRef
48.
Paparo L, Di Cotanzo M, Di Scala C et al (2014) The influence of early life nutrition on epigenetic regulatory mechanisms of the immune system. Nutrients 6:4706–4719PubMedCentralPubMedCrossRef
49.
Daly K, Shirazi-Beechey SP (2006) Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA Cell Biol 25:49–62PubMedCrossRef
50.
Russo I, Luciani A, de Cicco P, Troncone E, Ciacci C (2012) Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn’s mucosa through modulation of antioxidant defense machinery. PLoS ONE 7, e32841PubMedCentralPubMedCrossRef
51.
Chang PV, Hao L, Offermanns S, Medzhitov R (2014) The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 111:2247–2252PubMedCentralPubMedCrossRef
52.
Furusawa Y, Obata Y, Fukuda S et al (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450PubMedCrossRef
53.
54.
Leonard MT, Davis-Richardson AG, Ardissone AN et al (2014) The methylome of the gut microbiome: disparate Dam methylation patterns in intestinal Bacteroides dorei. Front Microbiol 5:361PubMedCentralPubMedCrossRef
55.
Murphy J, Mahony J, Ainsworth S, Nauta A, van Sinderen D (2013) Bacteriophage orphan DNA methyltransferases: insights from their bacterial origin, function, and occurrence. Appl Environ Microbiol 79:7547–7555PubMedCentralPubMedCrossRef
56.
Marinus MG, Casadeus J (2009) Roles of DNA adenine methylation in host-pathogen interactions: mismatch repair, transcriptional regulation, and more. FEMS Microbiol Rev 33:488–503PubMedCentralPubMedCrossRef
57.
Rakyan VK, Beyan H, Down TA et al (2011) Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet 7, e1002300PubMedCentralPubMedCrossRef
58.
Stefan M, Zhang W, Concepcion E, Yi Z, Tomer Y (2014) DNA methylation profiles in type 1 diabetes twins point to strong epigenetic effects in etiology. J Autoimmun 50:33–37PubMedCentralPubMedCrossRef
Metadata
Title
A model for the role of gut bacteria in the development of autoimmunity for type 1 diabetes
Authors
Austin G. Davis-Richardson
Eric W. Triplett
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3614-8

Other articles of this Issue 7/2015

Diabetologia 7/2015 Go to the issue

Article

Deletion of the gene for adiponectin accelerates diabetic nephropathy in the Ins2 +/C96Y mouse

Systematic Review

The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review

Short Communication

Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case–control study

Article

A proposal for the use of uniform diagnostic criteria for gestational diabetes in Europe: an opinion paper by the European Board & College of Obstetrics and Gynaecology (EBCOG)

Article

Polyphenol-rich diets improve glucose metabolism in people at high cardiometabolic risk: a controlled randomised intervention trial

Meta-analysis

Dietary fibre and incidence of type 2 diabetes in eight European countries: the EPIC-InterAct Study and a meta-analysis of prospective studies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits